Patents by Inventor Jennifer Matsuda

Jennifer Matsuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene
    Patent number: 11932867
    Abstract: Methods of preventing or treating rheumatoid arthritis (RA) in a subject by introducing the DRB1*04:01K71E mutation that is resistant to RA. The resistant allele is introduced into the subject having or at risk of developing RA, using a HLA CRISPR/Cas9 vector that targets codon 71 in the HLA allele DRB1*04:01, introducing a single A to G point mutation in codon 71 by homology directed repair to alter the lysine at position 71 of the expressed protein to glutamic acid. This modified allele is affected in the subject's hematopoietic stem cells, which are then expanded and transplanted back into the patient. This microgene therapy confers RA-resistance via an autologous transplant. The invention includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to modify the HLA DRB1*04:01 allele.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 19, 2024
    Assignees: National Jewish Health, The Regents of the University of Colorado, a Body Corporate
    Inventors: Brian Freed, Kirsten Anderson, Christina Roark, Jennifer Matsuda
  • Methods of Treating Rheumatoid Arthritis Using RNA-Guided Genome Editing of HLA Gene
    Publication number: 20200199616
    Abstract: Methods of preventing or treating rheumatoid arthritis (RA) in a subject by introducing the DRB1*04:01K71E mutation that is resistant to RA. The resistant allele is introduced into the subject having or at risk of developing RA, using a HLA CRISPR/Cas9 vector that targets codon 71 in the HLA allele DRB1*04:01, introducing a single A to G point mutation in codon 71 by homology directed repair to alter the lysine at position 71 of the expressed protein to glutamic acid. This modified allele is affected in the subject's hematopoietic stem cells, which are then expanded and transplanted back into the patient. This microgene therapy confers RA-resistance via an autologous transplant. The invention includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to modify the HLA DRB1*04:01 allele.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 25, 2020
    Inventors: Brian Freed, Kirsten Anderson, Christina Roark, Jennifer Matsuda